Kura Oncology Inc. Company Profile
NASDAQ: KURAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Kura Oncology at a glance
Kura Oncology Inc. (NASDAQ: KURA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in San Diego, CA. Kura Oncology is led by Dr. Troy Edward Wilson J.D., Ph.D. and employs about 260 people. At a market capitalization of $935.9 million, it is considered a small-cap company.
Its SEC Central Index Key (CIK) is 0001422143, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Kura Oncology do?
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.
Business description based on the company's public filings.
Company information
- Legal name
- Kura Oncology Inc.
- Ticker
- NASDAQ: KURA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Troy Edward Wilson J.D., Ph.D.
- Employees
- 260
- Headquarters
- 4930 Directors Place, San Diego, CA, United States
- Phone
- 858 500 8800
- Website
- kuraoncology.com
- Market cap
- $935.87M
- SEC CIK
- 0001422143
Companies similar to Kura Oncology
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ALMSAlumis Inc. | 7.16 | +2.73% | $926.76M | vs KURA |
| MLTXMoonLake Immunotherapeutics Class A | 10.82 | +2.27% | $920.85M | vs KURA |
| RIGLRigel Pharmaceuticals Inc. | 49.08 | +0.74% | $916.81M | vs KURA |
| ANROAlto Neuroscience Inc. | 24.37 | +1.41% | $956.33M | vs KURA |
| JBIOJade Biosciences Inc. | 14.39 | +1.70% | $915.17M | vs KURA |
| SPTXSeaport Therapeutics Inc. | 18.15 | +1.34% | $971.58M | vs KURA |
| CRVSCorvus Pharmaceuticals Inc. | 10.52 | +3.04% | $884.95M | vs KURA |
| CYRXCryoPort Inc. | 17.35 | +2.66% | $878.76M | vs KURA |